NEW ORLEANS, LA—The Impella CP percutaneous left ventricular assist device (pLVAD) does not reduce major adverse events when used in the setting of high-risk PCI, according to the CHIP-BCIS3 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results